WATCH Bleeding Episodes After Left Atrial Appendage Occlusion Versus Usual Care in Patients With Atrial FIBrillatIon and Severe to eNd-stage Chronic Kidney Disease (WatchAFIB in CKD)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Blood Coagulation Disorders
- Sponsor
- University of Magdeburg
- Enrollment
- 14
- Locations
- 4
- Primary Endpoint
- Frequency of occurrence of moderate and major bleedings (Type 2 to Type 5 according to the Bleeding Academic Research Consortium (BARC) definitions)
- Status
- Terminated
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the superiority of left atrial appendage occlusion in comparison to oral anticoagulation with a vitamin K antagonist (INR 2-3) related to the frequency of occurrence of at least one bleeding classified as moderate or major within 24 months.
Detailed Description
Open, randomized, controlled, multicenter clinical investigation. Transesophageal echocardiography (TEE) for all patients within 14 days of the Enrolment Visit. Patients randomized to oral anticoagulation (OAC) will receive standard of care (SOC) vitamin K antagonist treatment throughout the 24 months clinical investigation period, managed by the primary care physician, with the goal of achieving and maintaining an INR of 2-3 (INR monitoring by the primary care physician every two weeks throughout study period). Patients randomized to the WATCHMAN device will undergo device implantation within 48 hours of the screening TEE and after confirmation of INR ≤ 1.7 in the catheterization laboratory with a subsequent hospitalization for 24-48 hours. Concomitant treatment with Aspirin/Clopidogrel (managed by the patient's primary care physician) will be initiated on the day prior to device implantation, and will be continued for 6 months after the procedure, at which time Clopidogrel will be discontinued; administration of Aspirin will be continued indefinitely. Follow-up visits for all patients will take place on Day 45, and at Month 6, Month 12 and Month 24 (End of Study). Routine safety and efficacy assessments at each visit will be the same for all patients regardless of treatment group. Follow-up- visits at day 45, months 6, 12 and 24. Patients randomized to the WATCHMAN device will have additional TEE imaging performed at the Day 45 and Month 6 visits. An independent Data Monitoring Committee will monitor safety. A blinded and independent Endpoint Committee will evaluate end-points throughout the entire study period.
Investigators
Prof Dr Ruediger C. Braun-Dullaeus
Prof Dr
University of Magdeburg
Eligibility Criteria
Inclusion Criteria
- •Paroxysmal, persistent, or permanent non-valvular atrial fibrillation (AF), documented by electrocardiography performed at screening or within the prior 6 months
- •Indication for oral anticoagulation as assessed by CHA2DS2-VASc-Score (≥ 2)
- •Severe to end-stage chronic kidney disease (eGFR \< 30 ml/min as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula)
- •18 to 80 years, inclusive
- •Life expectancy of at least 2 years
- •Negative pregnancy test for women
- •Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent
- •Written informed consent
Exclusion Criteria
- •AF due to a reversible cause or a singular occurrence of AF
- •Conditions other than AF that require anticoagulation
- •Transient ischemic attack or stroke within previous 3 months
- •A need for Aspirin (at a dose of \> 162.5 mg/day) or for both Aspirin and Clopidogrel/other antiplatelet drugs (daily administration) other than for clinical investigation
- •Contraindications or allergies to vitamin K antagonists, Aspirin or Clopidogrel
- •Previous closure (surgical, interventional) of the left atrial appendage (LAA)
- •Previous closure of atrial septal defect (ASD) / persistent foramen ovale (PFO)
- •Active internal bleeding
- •Thrombocytopenia (\< 100,000 platelets/mm3)
- •History of or planned organ transplantation
Outcomes
Primary Outcomes
Frequency of occurrence of moderate and major bleedings (Type 2 to Type 5 according to the Bleeding Academic Research Consortium (BARC) definitions)
Time Frame: 24 months
Secondary Outcomes
- Frequency of at least one occurrence of a combined endpoint of moderate or major bleeding and/or severe cardiovascular adverse events (stroke, cardiac infarction, thrombosis, death)(24 months)